Table 1.

Clinical baseline characteristics of patients from the prospective Hamburg cohort

Clinical CharacteristicsComplete CohortTHSD7A-Associated MNTHSD7A-Ab–Negative MNP Value: THSD7A-Associated MN Versus
PLA2R1-Ab–Positive MNPLA2R1-Ab–Negative MNPLA2R1-Ab–Positive MNPLA2R1-Ab–Negative MN
No. of patients (%)345 (100)9 (2.6)259 (75.1)77 (22.3)
Age, yr, median, IQR57, 43–6847, 39–6155, 43–6758, 45–690.390.29
Men (%)232 (67)3 (33)180 (69)49 (64)0.020.08
Proteinuria, g/24 h, median, IQR6.4, 4.0–10.05.4, 4.0–6.96.9, 4.6–10.55.0, 2.8–7.60.190.99
Serum creatinine, mg/dl, median, IQR1.0, 0.8–1.30.8, 0.6–0.91.0, 0.8–1.31.0, 0.9–1.40.020.01
eGFR (CKD-EPI), ml/min per 1.73 m2, median, IQR81, 52–9896, 86–11782, 55–9975, 46–910.110.03
Patients with malignancy (%)25 (7.2)3 (33.3)14 (5.4)8 (10.4)<0.010.05
Time from renal biopsy to study inclusion, mo, median, IQR0.5, 0.0–1.00.75, 0.5–0.80.75 0.0–1.00.5 0.0–1.00.600.32
  • Patients with a newly diagnosed biopsy–proven MN were included in this cohort. None of the patients had received immunosuppressive therapy before the time of study inclusion. There were significantly more women in the patient cohort with THSD7A-associated MN compared with PLA2R1-Ab–positive patients. Patients with THSD7A-associated MN were younger and had lower proteinuria than patients with PLA2R1-associated MN, but these differences were not statistically significant. Serum creatinine was lower and eGFR was higher in patients with THSD7A-associated MN compared with in patients with PLA2R1-associated MN or patients who were negative for both PLA2R1-Ab and THSD7A-Ab. Patients with THSD7A-associated MN had a malignant disease significantly more often than patients with PLA2R1-associated MN. In these analyses, a Bonferroni adjustment was performed to account for multiple testing, according to which statistical significance is defined at P=0.03 (0.05/2; 2= no. of comparisons). IQR, interquartile range; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration.